| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Saad Latif, Muhammad Jahangeer, Dure Maknoon Razia, Mehvish Ashiq, Abdul Ghaffar, Muhammad Akram, Aicha El Allam, Abdelhakim Bouyahya, Larisa Garipova, Mohammad Ali Shariati, Muthu Thiruvengadam, Mohammad Azam Ansar. Dopamine in Parkinson's disease. Clinica chimica acta; international journal of clinical chemistry. vol 522. 2021-09-28. PMID:34389279. |
compared to other monoamines, dopamine is widely distributed in the olfactory bulb, midbrain substantia nigra, hypothalamus, vta, retina, and the periaqueductal gray area. |
2021-09-28 |
2023-08-13 |
Not clear |
| Liche Zhou, Guanglu Li, Yuyao Zhang, Miao Zhang, Zhichun Chen, Lina Zhang, Xiaojin Wang, Ming Zhang, Guanyu Ye, Yuanyuan Li, Shengdi Chen, Biao Li, Hongjiang Wei, Jun Li. Increased free water in the substantia nigra in idiopathic REM sleep behaviour disorder. Brain : a journal of neurology. vol 144. issue 5. 2021-09-23. PMID:33880500. |
we tested the associations between posterior substantia nigra free water and uptake of striatal dopamine transporter in idiopathic rem sleep behaviour disorder. |
2021-09-23 |
2023-08-13 |
human |
| Liche Zhou, Guanglu Li, Yuyao Zhang, Miao Zhang, Zhichun Chen, Lina Zhang, Xiaojin Wang, Ming Zhang, Guanyu Ye, Yuanyuan Li, Shengdi Chen, Biao Li, Hongjiang Wei, Jun Li. Increased free water in the substantia nigra in idiopathic REM sleep behaviour disorder. Brain : a journal of neurology. vol 144. issue 5. 2021-09-23. PMID:33880500. |
in addition, we observed significantly negative associations between posterior substantia nigra free-water values and dopamine transporter striatal binding ratios in the idiopathic rem sleep behaviour disorder patients. |
2021-09-23 |
2023-08-13 |
human |
| b' Macarena L Herrera, Romina Deza-Ponzio, Marisa S Ghersi, Emilce A de la Villarmois, Miriam B Virgolini, Mariela F P\\xc3\\xa9rez, Victor A Molina, Mar\\xc3\\xada J Bellini, Claudia B Here\\xc3\\xb1\\xc3\\xb. Early Cognitive Impairment Behind Nigrostriatal Circuit Neurotoxicity: Are Astrocytes Involved? ASN neuro. vol 12. 2021-09-15. PMID:32466659.' |
we evaluated tyrosine hydroxylase (th) as a dopamine marker, aldehyde dehydrogenase 2 (aldh2), a mitochondria detoxification enzyme and astrocyte glial fibrillar acid protein (gfap) an immunoreactivity marker involved in different areas: cpu, substantia nigra, prefrontal cortex, and hippocampus. |
2021-09-15 |
2023-08-13 |
Not clear |
| Aishwarya S Kulkarni, Maria Del Mar Cortijo, Elizabeth R Roberts, Tamara L Suggs, Heather B Stover, José I Pena-Bravo, Jennifer A Steiner, Kelvin C Luk, Patrik Brundin, Daniel W Wesso. Perturbation of in vivo Neural Activity Following α-Synuclein Seeding in the Olfactory Bulb. Journal of Parkinson's disease. vol 10. issue 4. 2021-09-15. PMID:32925105. |
parkinson's disease (pd) neuropathology is characterized by intraneuronal protein aggregates composed of misfolded α-synuclein (α-syn), as well as degeneration of substantia nigra dopamine neurons. |
2021-09-15 |
2023-08-13 |
mouse |
| Yingjie Han, Tian Wang, Chunyan Li, Zhenhua Wang, Yue Zhao, Jie He, Li Fu, Bing Ha. Ginsenoside Rg3 exerts a neuroprotective effect in rotenone-induced Parkinson's disease mice via its anti-oxidative properties. European journal of pharmacology. vol 909. 2021-09-10. PMID:34391769. |
ginsenoside rg3 treatment augmented the number of tyrosine hydroxylase-positive neurons in the substantia nigra (p < 0.01), mean density of tyrosine hydroxylase-positive nerve fibers (p < 0.01), and dopamine content (p < 0.01) in the striatum and reduced the reactive oxygen species level in the substantia nigra (p < 0.01). |
2021-09-10 |
2023-08-13 |
mouse |
| Linlin Zhang, Yanan Zheng, Junxia Xie, Limin Sh. Potassium channels and their emerging role in parkinson's disease. Brain research bulletin. vol 160. 2021-08-31. PMID:32305406. |
parkinson's disease (pd) is the second most common neurodegenerative disorder, which is associated with a selective loss of dopaminergic neurons in the substantia nigra (sn) and a reduction of dopamine in the striatum. |
2021-08-31 |
2023-08-13 |
Not clear |
| Peter A Barbuti, Roger A Barker, Patrik Brundin, Serge Przedborski, Stella M Papa, Lorraine V Kalia, Hideki Mochizuk. Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society. vol 36. issue 8. 2021-08-31. PMID:33963552. |
these criteria include reproducibly producing sufficient numbers of cells with an authentic substantia nigra dopamine neuron a9 phenotype, which can integrate into the host brain after transplantation and form synapses (considered crucial for long-term functional benefits). |
2021-08-31 |
2023-08-13 |
Not clear |
| Neil P Oxtoby, Louise-Ann Leyland, Leon M Aksman, George E C Thomas, Emma L Bunting, Peter A Wijeratne, Alexandra L Young, Angelika Zarkali, Manuela M X Tan, Fion D Bremner, Pearse A Keane, Huw R Morris, Anette E Schrag, Daniel C Alexander, Rimona S Wei. Sequence of clinical and neurodegeneration events in Parkinson's disease progression. Brain : a journal of neurology. vol 144. issue 3. 2021-08-13. PMID:33543247. |
the model estimates that parkinson's progression in patients at elevated risk for dementia starts with classic prodromal features of parkinson's disease (olfaction, sleep), followed by early deficits in visual cognition and increased brain iron content, followed later by a less certain ordering of neurodegeneration in the substantia nigra and cortex, neuropsychological cognitive deficits, retinal thinning in dopamine layers, and further deficits in visual cognition. |
2021-08-13 |
2023-08-13 |
human |
| Molly Von Seggern, Carlye Szarowicz, Matthew Swanson, Samantha Cavotta, Schuyler T Pike, Jennifer T Lambert. Purine molecules in Parkinson's disease: Analytical techniques and clinical implications. Neurochemistry international. vol 139. 2021-08-11. PMID:32650026. |
pd is characterized by loss of neurons in the substantia nigra and dopamine deficiency in the striatum. |
2021-08-11 |
2023-08-13 |
human |
| Sejal Patel, Derek Howard, Leon Frenc. A pH-eQTL Interaction at the Frontiers in aging neuroscience. vol 13. 2021-07-27. PMID:34305570. |
a ph-eqtl interaction at the parkinson's disease causes severe motor and cognitive disabilities that result from the progressive loss of dopamine neurons in the substantia nigra. |
2021-07-27 |
2023-08-13 |
Not clear |
| Christian U von Linstow, Merritt DeLano-Taylor, Jeffrey H Kordower, Patrik Brundi. Does Developmental Variability in the Number of Midbrain Dopamine Neurons Affect Individual Risk for Sporadic Parkinson's Disease? Journal of Parkinson's disease. vol 10. issue 2. 2021-07-26. PMID:31958098. |
parkinson's disease (pd) is a slowly progressing neurodegenerative disorder that is coupled to both widespread protein aggregation and to loss of substantia nigra dopamine (da) neurons, resulting in a wide variety of motor and non-motor signs and symptoms. |
2021-07-26 |
2023-08-13 |
Not clear |
| Mahsa Dadar, Janis Miyasaki, Simon Duchesne, Richard Camiciol. White matter hyperintensities mediate the impact of amyloid ß on future freezing of gait in Parkinson's disease. Parkinsonism & related disorders. vol 85. 2021-07-22. PMID:33770671. |
previous studies have reported relationships between fog, substantia nigra (sn) degeneration, dopamine transporter (dat) concentration, as well as amyloid β deposition. |
2021-07-22 |
2023-08-13 |
Not clear |
| Yanyun Sun, Xiao-Jun Lu, Xinghui Fu, Ye Zhang, Yan Zhan, Jiabing Liu, Lingxia Zhao, Chun-Lin Xi. Engrafted primary type-2 astrocytes improve the recovery of the nigrostriatal pathway in a rat model of Parkinson's disease. Molecular and cellular biochemistry. vol 476. issue 2. 2021-07-19. PMID:33070275. |
parkinson's disease (pd) is a disorder characterized by a progressive loss of the dopaminergic neurons in the substantia nigra and a depletion of the neurotransmitter dopamine in the striatum. |
2021-07-19 |
2023-08-13 |
rat |
| Rayul Wi, Young Cheul Chung, Byung Kwan Ji. Functional Crosstalk between CB and TRPV1 Receptors Protects Nigrostriatal Dopaminergic Neurons in the MPTP Model of Parkinson's Disease. Journal of immunology research. vol 2020. 2021-07-12. PMID:33062722. |
mptp induced a significant loss of nigrostriatal dopamine neurons and glial activation in the substantia nigra (sn) and striatum (str) as visualized by tyrosine hydroxylase (th) or macrophage antigen complex-1 (mac-1) or glial fibrillary acidic protein (gfap) immunocytochemistry, respectively. |
2021-07-12 |
2023-08-13 |
mouse |
| Bruk Getachew, Antonei B Csoka, Amna Bhatti, Robert L Copeland, Yousef Tizab. Butyrate Protects Against Salsolinol-Induced Toxicity in SH-SY5Y Cells: Implication for Parkinson's Disease. Neurotoxicity research. vol 38. issue 3. 2021-07-09. PMID:32572814. |
parkinson's disease (pd), a progressive neurodegenerative disorder, is associated with the destruction of dopamine neurons in the substantia nigra (sn) and the formation of lewy bodies in basal ganglia. |
2021-07-09 |
2023-08-13 |
human |
| Rebecca D Howell, Sergio Dominguez-Lopez, Sarah R Ocañas, Willard M Freeman, Michael J Beckstea. Female mice are resilient to age-related decline of substantia nigra dopamine neuron firing parameters. Neurobiology of aging. vol 95. 2021-07-09. PMID:32846275. |
female mice are resilient to age-related decline of substantia nigra dopamine neuron firing parameters. |
2021-07-09 |
2023-08-13 |
mouse |
| Atsushi Takeda, Masahiko Tomiyama, Ritsuko Hanajim. [The Relationship Between Pathophysiology and Neurotransmitters in Parkinson's Disease]. Brain and nerve = Shinkei kenkyu no shinpo. vol 73. issue 7. 2021-07-09. PMID:34234041. |
the major motor symptoms of pd are mainly caused by dopamine (da) deficiency due to the loss of dopaminergic neurons in the substantia nigra. |
2021-07-09 |
2023-08-13 |
Not clear |
| Yiqiu Liu, Junyu Deng, Ye Liu, Wei Li, Xuqiang Ni. FGF, Mechanism of Action, Role in Parkinson's Disease, and Therapeutics. Frontiers in pharmacology. vol 12. 2021-07-09. PMID:34234672. |
the death or dysfunction of dopaminergic neurons in the dense part of the substantia nigra leads to dopamine deficiency in the basal ganglia and motor dysfunction. |
2021-07-09 |
2023-08-13 |
Not clear |
| Steven Vetel, Laura Foucault-Fruchard, Claire Tronel, Frédéric Buron, Jackie Vergote, Sylvie Bodard, Sylvain Routier, Sophie Sérrière, Sylvie Chalo. Neuroprotective and anti-inflammatory effects of a therapy combining agonists of nicotinic α7 and σ1 receptors in a rat model of Parkinson's disease. Neural regeneration research. vol 16. issue 6. 2021-07-03. PMID:33269756. |
although no effect was noticed in the amphetamine-induced rotation test, our data has shown that the pha/pre treatment induced partial protection of the dopaminergic neurons (15-20%), assessed by the dopamine transporter density in the striatum and immunoreactive tyrosine hydroxylase in the substantia nigra. |
2021-07-03 |
2023-08-13 |
rat |